ECE2017 Eposter Presentations: Reproductive Endocrinology Endocrine tumours and neoplasia (2 abstracts)
Study of CYP17 and PSA G158A polymorphisms in prostate cancer
Suzana Vladoiu 1 , Dana Manda 1 , Sabina Oros 1 , Sorina Schipor 1 , Adrian Preda 3 , Ismail Gener 3 , Catalina Picu 1 , Roxana Rosca 1, & Corin Badiu 1,
1‘C.I.Parhon’ National Institute of Endocrinology, Bucharest, Romania; 2‘Carol Davila’ University of Medicine and Farmacy, Bucharest, Romania; 3Clinical Institute Fundeni, Bucharest, Romania.
The relationship between the level of genetic variation in CYP17, PSA genes and prostate cancer has been extensively studied but the results are still unclear. A 450c17a (CYP17) polymorphism A1/A2 was described to be significantly associated to prostate cancer. A SNP in the promotor PSA gene is an A to G substitution at position −158 (G158A) was proposed to interact differently with AR, thereby modifying the expression pattern and occurrence of prostate cancer.
Objective: The aim of the study was to investigate the association between CYP17 and PSA gene polymorphisms with advanced prostate cancer.
Subjects and methods: The study was conducted on 48 patients with advanced prostate cancer (Gleason score > 7) and 13 benign prostate hyperplasia subjects. Patients were enrolled after they gave their informed consent. DNA was isolated from prostatic tissue with PureLink Genomic DNA (Invitrogen). Genotyping of the A1/A2 and G/A polymorphisms in the promoter region of CYP17 and the PSA, respectively, were determined by a PCR–RFLP assay. PCR product was digested with restriction enzyme NheI (PSA G-158A) and MspA1I (CYP17). Preoperatory serum PSA was assayed by immunochemiluminescence.
Results: Genotype distribution differ for PSA G-158 between the prostate cancer and the control group (25% GG, 25% AA, 50% AG vs. 8% GG, 23% AA, 69% AG) and for CYP 17 (36% A1, 45% A1A2, 19% A2 vs. 22% A1, 64% A1A2, 14% A2). The frequency of A1 allele was 0.41, and 0.59 for A2 allele. In control group the frequency of A1 allele in population was 0.46, for A2 allele the frequency was 0.54. Neither CYP17 nor PSA polymorphisms associated with prostate cancer. Serum levels of PSA did not differ between genotypes.
Conclusion: In our study groups CYP17 and PSA gene polymorphisms did not significantly associated with prostate cancer or serum PSA levels. Further studies are needed on larger cohorts.
Acknowledgement
This work was funded by UEFISCDI grant no. 192/2014
Volume 49
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more